Efficacy and Safety Profile of Ticagrelor Versus Clopidogrel in Percutaneous Coronary Intervention (PCI) for Acute Coronary Syndrome (ACS): A Systematic Review and Meta-Analysis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy and Safety Profile of Ticagrelor Versus Clopidogrel in Percutaneous Coronary Intervention (PCI) for Acute Coronary Syndrome (ACS): A Systematic Review and Meta-Analysis

Published:2023-10-04 Issue: Volume: Page:
ISSN:2168-8184
Container-title:Cureus
language:en
Short-container-title:

Author:

Maqbool Shahzaib,Ali Muhammad Sajjad,Rehman Abdur,Ur Rehman Mohammad Ebad,Iqbal Javed,Razzaq Azeen,Kamal Amer,Shivamadhu Shivani Shivamadhu,Afzal Maham,Fazal Faizan,Basit Jawad,Khalid Syed Aizaz

Publisher

Springer Science and Business Media LLC

Subject

Aerospace Engineering

Reference26 articles.

1. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation;Collet JP;Eur Heart J,2021

2. ACC/AHA versus ESC guidelines on dual antiplatelet therapy: JACC Guideline Comparison;Capodanno D;J Am Coll Cardiol,2018

3. Safety and effectiveness of contemporary P2Y(12) inhibitors in an East Asian population with acute coronary syndrome: a nationwide population-based cohort study;Yun JE;J Am Heart Assoc,2019

4. Ticagrelor versus clopidogrel in patients with acute coronary syndromes;Wallentin L;N Engl J Med,2009

5. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS);Valgimigli M;Eur Heart J,2018

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP